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INTRODUCTION
Irritable bowel syndrome (IBS) is associated with a variable 
combination of  chronic or recurrent symptoms such as 
abdominal pain, bloating, constipation and diarrhea. There 
is generally no structural or biochemical abnormality 
detected by conventional laboratory tests. IBS is one of  
the most common functional gastrointestinal disorders 
accounting for 3% of  all primary consultations[1]. In 
western countries, the prevalence of  IBS is around 10%, 
depending upon the defi nition used[2].  Moreover, there is 
increasing prevalence of  IBS in the newly developed Asian 
countries[3]. The potential etiological factors include stress, 
anxiety, visceral hypersensitivity, altered bowel motility, 
neurotransmitter imbalances, and infl ammation. 
Herbal medicines have been used in Asia for a long 
time. An increasing number of  IBS patients are beginning 
to receive complementary and alternative medicines in the 
West, most frequently herbal remedies (43%)[4]. Patients 
may seek HM for symptomatic relief  when conventional 
medicines (CM) are unsuccessful. In such situations, 
an important question is whether herbal medicines are 
effective and safe for IBS patients. In the present study, 
we systematically reviewed the literature and evaluated the 
effects of  HM as well as their potential adverse events in 
patients with irritable bowel syndrome.
MATERIALS AND METHODS
Search strategy
We carried out a literature search using MEDLINE 
(1966-2005), EMBASE (1980-2005), Cochrane Database 
(1992-2005), TCMLARS Database (1984-2005), CJA Full-
Text Database (1994-2005), and Chongqing VIP Database 
(1989-2005) for relevant randomized controlled clinical 
trials, meta-analysis and systematic reviews published in 
all languages until October 2005. We used MeSH terms 
including ‘irritable bowel syndrome, functional colonic 
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Abstract
AIM: To explore the efficacy and safety of herbal 
medicines (HM) in the treatment of irritable bowel 
syndrome (IBS).
METHODS: A computer-based as well as manual 
literature search was performed. We reviewed randomized 
controlled trials on the treatment of IBS with and without 
HM.
RESULTS: A total of 22 studies with 25 HMs met the 
inclusion criteria. Four of these studies were of good 
quality, while the remaining 18 studies involving 17 
Chinese herbal medicine (CHM) formulas were of poor 
quality. Eight of these reports using 9 HMs showed 
global improvement of IBS symptoms, 4 studies with 3 
HMs were effi cacious in diarrhea-predominant IBS, and 2 
studies with 2 HMs showed improvement in constipation-
predominant IBS. Out of a total of 1279 patients, 15 
adverse events in 47 subjects were reported with HM. 
No serious adverse events or abnormal laboratory tests 
were observed. The incidence of the adverse events was 
low (2.97%; 95% CI: 2.04%-3.90%).
CONCLUSION: Herbal medicines have therapeutic 
benefi t in IBS, and adverse events are seldom reported 
in literature. Nevertheless, herbal medicines should be 
used with caution. It is necessary to conduct rigorous, 
well-designed clinical trials to evaluate their effectiveness 
and safety in the treatment of IBS.
© 2008 WJG. All rights reserved.
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disease, drugs, Chinese medicines, traditional medicines, 
herbal medicines, alternative medicines, complement 
medicines, plant, oriental traditional medicine’ for the 
database search. 
In addition, a hand search of  reference lists, review 
articles, editorials and abstracts from major meetings was 
also conducted to supplement the electronic search. We 
included articles published in all languages. Titles and 
abstracts of  all potentially relevant studies were screened 
before retrieval of  the full articles. However, if  the title 
and the abstract were ambiguous, the full articles were 
scrutinized. Two independent reviewers (J.S and H-X. L) 
participated in the literature search. Any disagreements 
were resolved by discussions in order to reach a consensus.
Inclusion and exclusion criteria
The following inclusion criteria were used: (1) Diagnostic 
criteria used for IBS were ROME?[5] or ROME?[6] 
criteria or the 1986 National symposium on chronic 
diarrhea (Chengdu China) criteria[7]; (2) Study design 
with randomized controlled clinical trials, irrespective of  
blinding; (3) Studies using HM alone for treating IBS in 
the treatment groups; (4) Identification and description 
of  adverse events; (5) The treatment group received 
orally administered HM; (5) The control groups received 
placebo, CM or no treatment.
We excluded studies in which HM was used in 
combination with CMs, in children and in control groups. 
Administration of  HM by other routes such as injections 
were also excluded.
Information on HM products derived from a single 
herb, Chinese proprietary medicines, complex extracts 
of  different herb preparations such as decoction, tablet, 
capsule, pill, powder and plaster were collected. Standardized 
extracts of  whole plants were included, but isolated ‘active’ 
phytochemical ingredients were excluded as these are 
generally considered as plant chemical products. 
Data extraction
Data was collected independently by the reviewers. Any 
disagreement between the reviewers was resolved by 
discussion in order to achieve consensus. 
Assessment of study quality
The reviewers also assessed independently the quality of  
each study by Jadad scale[8] and Cochrane Handbook[9].
Statistical analysis 
The relative risk (RR) and 95% confi dence interval (95% 
CI) were calculated using raw data derived from each study. 
Intention-to-treat analysis was performed if  possible. 
Meta-analyses was performed with either fixed effects 
model or random effects model according to the presence 
or absence of  heterogeneity when HM was compared with 
control. Statistical analysis was performed with RevMan 4.2 
to detect any bias in studies using the funnel plot. 
RESULTS
Our initial search generated 572 citations. After analyzing 
the titles and abstracts, and reading the full text articles, 
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only 22 studies[10-31] with 25 arms involving 1279 patients 
and 763 controls met the predefined inclusion criteria. 
Eighteen of  the studies were conducted in China and 
published in Chinese, four were published in English, 
one each from Australia[11] and Israel[20], and two from 
Germany[29,31] (Table 1).
Three studies[11,20,29] used computer software and 
two[21,25] used random number tables to generate the 
allocation sequence. Four studies[11,20,29,31] used an adequate 
concealed allocation method of  randomization. Six 
studies[11-12,20,27,29,31] used placebo as control, four of  these 
studies[11,20,29,31] were considered to be adequate, while 
two[12,27] demonstrated an inadequate comparison between 
placebo and CTM decoction; Four studies[11,20,29,31] provided 
statistical data with intention-to-treat protocol.
Using the Jadad Score and Cochrane handbook, four 
studies[11,20,29,31] were judged to be of  high quality, whereas 
the remaining reports were of  poor quality.
Effi cacy of herbal medicines
Global symptoms of  IBS:  Two studies[11,29] with 3 HMs 
showed significant benefit compared to placebo with 
respect to the global improvement of  IBS symptoms: 
standard CHM formula[11] (RR 2.15; 95% CI: 1.26-3.65 
rated by patient and RR 2.62; 95% CI: 1.44-4.78 assessed by 
gastroenterologist), STW5[29] (RR 1.68; 95% CI: 1.13-2.51), 
STW5-?[29] (RR 1.90; 95% CI: 1.30-2.78) (Figure 1). The 
following seven CHMs using complex herbal formulas 
appeared to be effective in improving global IBS symptoms 
compared to CM: Lizhong huoxie decoction[10] (RR 1.40; 
95% CI: 1.11-1.76), Huatan Liqi Tiaofu decoction[13] 
(RR 1.24; 95% CI: 1.05-1.47), Geqin Shujiang Saocao 
decoction[14] (RR 1.24; 95% CI: 1.05-1.47), Huanchang 
decoction[16] (RR 1.41; 95% CI: 1.08-1.84), Congpi Lunzhi 
Formula[17], (RR 1.74; 95% CI: 1.35-2.24), Xiangsha Liujunzi 
decoction[18] (RR 1.28; 95% CI: 1.00-1.63, P = 0.015), and 
Shunji mixture[19] (RR 1.23; 95% CI: 1.01-1.49).
By contrast, the following compounds were not 
effective in the treatment of  global IBS symptoms 
compared to placebo or CM: Individualized CHM[11] (RR 
1.51; 95% CI: 0.83-2.73 assessed by patients and RR 1.54; 
95% CI: 0.77-3.05 assessed by gastroenterologist), Bitter 
candytuft[29] (RR 1.23; 95% CI: 0.78-1.92), Curcuma [31] (RR 
0.97; 95% CI: 0.60-1.55), Fumitory[31] (RR 1.13; 95% CI: 
0.74-1.72) (Figure 1), Changkang Capsule[21] (RR 1.03; 95% 
CI: 0.92-1.14), and Jiejing Yiji decoction[30] (RR 1.09; 95% 
CI: 0.96-1.23) (Figure 2). 
Diarrhea: As shown in Figure 3, a meta-analysis of  Tongxie 
Yaofang modified decoction[12] and Tongxie Yaofang plus 
Sini San decoction[27] (RR 1.14; 95% CI: 1.04-1.24) showed 
that compared to CM these products had antidiarrheal 
effects in patients with diarrhea-predominant IBS patients. 
We combined the data from these two studies[12,27] since 
their herbal ingredients and dosages were very similar. Their 
effects were similar to Liyiting decoction[26] (RR 1.28; 95% 
CI: 1.02-1.62), and Tongxie yihao capsule[28] (RR 1.22; 95% 
CI: 1.01-1.46). 
Three studies demonstrated an insignificant improve-
ment in diarrhea: Xianshi Capsule[15] (RR 1.20; 95% CI: 
0.98-1.48), Changning Yin decoction[24] (RR 1.19; 95% 
CI: 0.99-1.42), Changjitai decoction[25] (RR 1.14; 95% CI: 
0.81-1.60) (Figure 3).
Constipation: One study[20] showed that compared 
to placebo Padma Lax was more effective in relieving 
symptoms in patients with constipation-predominant 
IBS (RR 7.24; 95% CI: 2.37-22.12) (Figure 4). Similarly, 
another study[23] demonstrated that Gegan Qinlian pellet 
was therapeutically effective (RR 1.28; 95% CI: 1.03-1.60). 
By contrast, Wuma Simo decoction[22] had no advantages 
over CMs in the patients with constipation-predominant 
IBS (RR 1.07; 95% CI: 0.91-1.25) (Figure 5).
Therapeutic period and follow-up
The duration of  treatment was 8 weeks or more in five 
studies[11,15,20,25,31], and 5 or 6 wk in three studies[17,24,26]. In 
one study[16] the treatment duration was 3-6 wk, whereas 
the other studies[10,12-14,19,21,23,28,29] lasted 3 or 4 wk, while 
the shortest[18,22,27,30] period of  the treatment was only 
2 wk. Five studies[10-11,16,28,30] reported follow-up assessment 
after herbal medicine treatment. Two[10,28] reported that 
the symptom recurrence rates were lower in the treatment 
group compared to the conventional treatment group 
(25.5% vs 60%; 23.1% vs 50%, P < 0.01), after one-year 
and one-half-year respectively, following completion of  
the treatment. Another study[11] presented the result as 
bowel symptom scale. There was signifi cant improvement 
in the individualized group (75%), and standard group 
(63%) compared with placebo group (32%) after 14 wk of  
follow-up. One study[16] reported the number of  subjects 
that were lost to follow-up, but the reasons were not 
provided. Another study[30] reported symptom recurrence 
in 3 of  48 patients in the treatment group after 2 wk 
without treatment.
Table 1  Characteristics of studies included in the analysis
Study ID Year n Mean
age
Sex
(male %)
Study
quality
Herbal medicine Type of 
herbs
Control Length
(wk)
Follow-up 
(wk)
Gao[10] 1992 111 34 39 L Lizhong Huoxie decoction C.F Oryzanol, Nifedipine   4 52
Bensoussan[11] 1998 116 47 35 H Individualized CHM C.F Placebo 16 14
Standard Formula C.F
Zhao[12] 2000 233 39 34 L Tongxie Yaofang 
modifi ed decoction
C.F Salazosulfapyridine   3 n.r
Diphenoxylate, Anisodamine, 
Amitriptyline, Placebo
Lei[13] 2000   96 39 56 L Huatan Liqi Tiaofu decoction C.F Smecta   3 n.r
Wang[14] 2000   96 39 49 L Geqin Shujiang Shaocao decoction C.F Smecta, vitB   3 n.r
Ye[15] 2002   80 37 46 L Xianshi Capsule C.F Dicetel, Smecta   8 n.r
Deng[16] 2002   62 38 35 L Huanchang decoction C.F Anisodamine, Oryzanol      3-6 52
Zeng[17] 2002   98 38 46 L Congpi Lunzhi Formula C.F Bacillus Licheniformis   6 n.r
Ge[18] 2002   57 40 44 L Xiangsha Liujunzi decoction C.F Diazepam, Propantheline, 
Domperidone
  2 n.r
Zhou[19] 2002 105 n.r n.r L Shunji mixture C.F Bitinal   4 n.r
Sallon[20] 2002   80 47.9 ± 2.11 38 H Padma Lax (Tibetan 
herbal formula)
C.E Placebo 12  n.r
46.3 ± 2.93
Ma[21] 2003 204 36 48 L Changkang Capsule C.F Amitriptyline   4 n.r
Wang[22] 2003 104 53 53 L Wuma Simo decoction C.F Cisapride   2 n.r
Liu[23] 2003   77 37 36 L Gegan Qinlian Pellet C.F Nifedipine   3 n.r
Li[24] 2003 101 39 68 L Changning Yin decoction C.F Diphenoxylate   5 n.r
Shen[25] 2003   47 41.6 ± 12.81 57 L Changjitai decoction C.F Dicetel   8 n.r
42.3 ± 14.73
Zhao[26] 2004   84 44 44 L Liyiting decoction C.F Dicetel   6 n.r
Xiao[27] 2004 167 37 41 L Tongxie Yaofang plus sini san 
decoction (similar with Tongxie 
Yaofang modifi ed decoction) 
C.F Salazosulfapyridine
Diphenoxylate, Anisodamine,
Amitriptyline, Placebo
  2 n.r
Gao[28] 2004   98 36 35 L Tongxie yihao capsule C.F Dicetel, Domperidone, 
Loperamide, Doxepin
  4 24
Madisch[29] 2004 208 47 40 H 1 STW5 C.E Placebo   4 n.r
2 STW5-? C.E
3 Bitter Candytuft M.E
Bo[30] 2004   92  38.8 ± 1.71 41 L Jiejing Yiji decoction C.F Cerekinon   2   4
 41.3 ± 1.73
Brinkhaus[31] 2005 106 47.2 ± 11.71 37 H 1 Curcama M.E Placebo 18 n.r
49.5 ± 14.52 2 Fumitory M.E
 49.0 ± 9.13
H: High quality study; L: Low quality study; C.F: Complex formulation of herbs; C.E: Complex extracts of different herbs; M.E: Mono-extract of single herb. 1The 
fi rst treatment group; 2The second treatment group; 3The control group; n.r: Not reported.
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Adverse effects of herbal medicine
In the total study group of  1279 patients, only 15 adverse 
events in 47 subjects were observed (Table 2). The most 
common symptoms were abdominal distention, constipation 
and abdominal pain. None of  the subjects developed any 
serious adverse events or abnormal laboratory tests. The 
percentage of  adverse events associated with HM was 3.67% 
(95% CI: 2.64-4.71%) in the 1279 patients in the different 
treatment groups.
Bias analysis
Funnel plots indicated an asymmetry (Figure 6).
01 Individualized CHM Formula (Rated by Patient)
     Bensoussan 1998[11]  18/38  11/35
Subtotal (95% CI)   38  35
Total events: 18 (HM), 11 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P  = 0.18)
02 Individualized CHM Formula (Rated by Gastroenterologist)
     Bensoussan 1998[11]  15/38    9/35 
Subtotal (95% CI)   38  35
Total events: 15 (HM), 9 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P  = 0.22)
03 Standard CHM Formula (Rated by Patient)
     Bensoussan 1998[11]  29/43  11/35 
Subtotal (95% CI)   43  35
Total events: 29 (HM), 11 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P  = 0.005)
04 Standard CHM Formula (Rated by Gastroenterologist)
     Bensoussan 1998[11]  29/43    9/35 
Subtotal (95% CI)   43  35
Total events: 29 (HM), 9 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.15 (P  = 0.002)
05 STW5
     Madisch 2004[29]   33/51  20/52 
Subtotal (95% CI)   51  52
Total events: 33 (HM), 20 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.55 (P  = 0.01)
06 STW5-II
     Madisch 2004[29]   38/52  20/52  
Subtotal (95% CI)   52  52
Total events: 38 (HM), 20 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.30 (P  = 0.0010)
07 Bitter Candytuft
     Madisch 2004[29]   25/53  20/52 
Subtotal (95% CI)   53  52
Total events: 25 (HM), 20 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P  = 0.37)
08 Curcuma
     Brinkhaus 2005[31]   12/24  30/58 
Subtotal (95% CI)   24  58
Total events: 12 (HM), 30 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P  = 0.89)
09 Fumitory
     Brinkhaus 2005[31]   14/24  30/58 
Subtotal (95% CI)   24  58
Total events: 14 (HM), 30 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P  = 0.57)
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100.00  0.97 [0.60, 1.55]
100.00  0.97 [0.60, 1.55]
100.00  1.13 [0.74, 1.72]
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Study    HM  Placebo       RR (fi xed)  Weight        RR (fi xed)
or sub-category   n /N     n /N         95% CI     %          95% CI
      0.1    0.2        0.5      1       2          5       10
       Favours placebo         Favours HM
Figure 1  Comparison of herbal medicine and placebo (Outcome: global improvement of symptoms). HM: Herbal medicine; RR: Relative risk; CI: Confi dence interval; Fixed: 
Fixed effects model.
Shi J et al.  Herbal medicines and IBS                                                                                                               457
www.wjgnet.com
DISCUSSION
In the present review, 3 out of  the 4 good quality 
studies[11,20,31] demonstrated 4 different herbal interventions: 
one Chinese herbal medicine (standard formula), one 
Tibetan herbal formula (Padma Lax) and two complex 
extracts of  herbs: STW5 and STW5-? which could 
potentially relieve abdominal pain, constipation, diarrhea 
and alternating constipation and diarrhea. Moreover, 
three[11,29,31] out of  these four studies showed that four 
01 Lizhong huoxie decoction
     Gao 1992[10]   67/72  26/39
Subtotal (95% CI)   72  39
Total events: 67 (HM), 26 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P  = 0.005)
02 Huatan Liqi Tiaofu decoction
     Lei 2000[13]   46/48  37/48 
Subtotal (95% CI)   48  48
Total events: 46 (HM), 37 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P  = 0.010)
03 Geqin Shujiang Saocao decoction
     Wang 2000[14]   46/48  37/48 
Subtotal (95% CI)   48  48
Total events: 46 (HM), 37 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P  = 0.010)
04 Huanchang decoction
     Deng 2002[16]   30/32  20/30 
Subtotal (95% CI)   32  30
Total events: 30 (HM), 20 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P  = 0.01)
05 Congpi Lunzhi Formula
     Zeng 2002[17]   49/50  27/48 
Subtotal (95% CI)   50  48
Total events: 49 (HM), 27 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.31 (P  < 0.0001)
06 Shunji mixture
     Zhou 2002[19]   54/60  33/45  
Subtotal (95% CI)   60  45
Total events: 54 (HM), 33 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P  = 0.04)
07 Xiangsha Liujunzi decoction
     Ge 2002[18]   35/36  16/21 
Subtotal (95% CI)   36  21
Total events: 35 (HM), 16 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P  = 0.05)
08 Changkang
     Ma 2003[21]   107/120  73/84 
Subtotal (95% CI)   120  84
Total events: 107 (HM), 73 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P  = 0.63)
09 Jiejing Yiji decoction
     Bo 2004[30]   48/50  37/42 
Subtotal (95% CI)   50  42
Total events: 48 (HM), 37 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P  = 0.18)
100.00  1.40 [1.11, 1.76]
100.00  1.40 [1.11, 1.76]
100.00  1.24 [1.05, 1.47]
100.00  1.24 [1.05, 1.47]
100.00  1.24 [1.05, 1.47]
100.00  1.24 [1.05, 1.47]
100.00  1.41 [1.08, 1.84]
100.00  1.41 [1.08, 1.84]
100.00  1.74 [1.35, 2.24]
100.00  1.74 [1.35, 2.24]
100.00  1.23 [1.01, 1.49]
100.00  1.23 [1.01, 1.49]
100.00  1.28 [1.00, 1.63]
100.00  1.28 [1.00, 1.63]
100.00  1.03 [0.92, 1.14]
100.00  1.03 [0.92, 1.14]
100.00  1.09 [0.96, 1.23]
100.00  1.09 [0.96, 1.23]
Study    HM  CM       RR (fi xed)  Weight        RR (fi xed)
or sub-category   n /N  n /N         95% CI     %          95% CI
      0.1    0.2         0.5     1        2           5       10
           Favours CM            Favours HM
Figure 2  Comparison of herbal medicine and conventional medicine (Outcome: Global improvement of symptoms). HM: Herbal medicine; CM: Conventional medicine; RR: 
Relative risk; CI: Confi dence interval; Fixed: Fixed effects model.
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interventions including one individualized formula and three 
mono-extracts of  single herb (Bitter Candytuft, Curcama 
and Fumitory) were not effective in IBS. We recognized that 
some complex herbal formulas may improve IBS symptoms, 
whereas three mono-extracts of  single herbs had no 
benefi cial effect. A possible explanation for these fi ndings is 
that the therapeutic effect may be enhanced by the synergic 
actions of  compounds in a mixture of  different herbs.
Twelve[10,12-14,16-19,23,26-28] out of  the 18 poor quality 
studies showed that some Chinese herbs formulas, such as, 
Huatan Liqi Tiaofu decoction, Tongxie Yaofang modifi ed 
and Tongxie Yaofang plus Sini San decoction, Geqin 
Shujiang Saocao decoction, Huanchang decoction, Congpi 
Lunzhi Formula, Xiangsha Liujunzi decoction, Shunji 
mixture, Gegan Qinlian Pellet, and Liyiting decoction were 
more benefi cial than CMs in the treatment of  IBS.
01 Tongxie Yaofang modifi ed decoction
     Zhao 2000[12]     67/68    50/59
     Xiao 2004[27]     44/46    40/46
Subtotal (95% CI)   114  105
Total events: 111 (HM), 90 (CM)
Test for heterogeneity: Chi-Square = 0.41, df = 1 (P  = 0.52)
Test for overall effect: Z = 2.96 (P  = 0.003)
02 Liyiting decoction
     Zhao 2004[26]     48/52    23/32 
Subtotal (95% CI)     52    32
Total events: 48 (HM), 23 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P  = 0.03)
03 Tongxie yihao capsule
     Gao 2004[28]     52/56    32/42 
Subtotal (95% CI)     56    42
Total events: 52 (HM), 32 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P  = 0.04)
04 Xianshi capsule
     Ye 2002[15]     36/40    30/40 
Subtotal (95% CI)     40    40
Total events: 36 (HM), 30 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P  = 0.08)
05 Changning Yin decoction
     Li 2003[24]     46/51    38/50 
Subtotal (95% CI)     51    50
Total events: 46 (HM), 38 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P  = 0.06)
06 Changjitai decoction
     Shen 2003[25]     25/30    11/15  
Subtotal (95% CI)     30    15
Total events: 25 (HM), 11 (CM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P  = 0.47)
  57.24  1.16 [1.04, 1.30]
  42.76  1.10 [0.97, 1.25]
100.00  1.14 [1.04, 1.24]
100.00  1.28 [1.02, 1.62]
100.00  1.28 [1.02, 1.62]
100.00  1.22 [1.01, 1.46]
100.00  1.22 [1.01, 1.46]
100.00  1.20 [0.98, 1.48]
100.00  1.20 [0.98, 1.48]
100.00  1.19 [0.99, 1.42]
100.00  1.19 [0.99, 1.42]
100.00  1.14 [0.81, 1.60]
100.00  1.14 [0.81, 1.60]
Study    HM  CM       RR (fi xed)  Weight        RR (fi xed)
or sub-category   n /N  n /N         95% CI     %          95% CI
      0.1    0.2         0.5     1        2          5       10
           Favours CM            Favours HM
Figure 3  Comparison of herbal medicine and conventional medicine (Outcome: diarrhea). HM: Herbal medicine; CM: Conventional medicine; RR: Relative risk; CI: 
Confi dence interval; Fixed: Fixed effects model.
01 Padma Lax (Tibetan herbal formula)
     Sallon 2002[20]   24/42    3/38 
Subtotal (95% CI)     
Total events: 24 (HM), 3 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.47 (P  = 0.0005)
100.00  7.24 [2.37, 22.12]
100.00  7.24 [2.37, 22.12]
Study    HM  Placebo       RR (fi xed)  Weight        RR (fi xed)
or sub-category   n /N     n /N         95% CI     %          95% CI
      0.1    0.2         0.5     1       2          5       10
          Favours Placebo             Favours HM
Figure 4  Comparison of herbal medicine and placebo (Outcome: constipation). HM: Herbal medicine; RR: Relative risk; CI: Confi dence interval; Fixed: Fixed effects model.
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However, these studies revealed several methodological 
flaws. We found that the longest duration of  treatment 
was 18 wk, while the shortest was just 2 wk, and only 
5 studies lasted more than 8 wk. The most frequent 
treatment duration was 3-4 wk. With such a short period 
of  treatment, it is hard to reach the therapeutic goal in 
IBS. Some studies reported the long-term effects of  herbs 
and the rate of  symptom recurrence. Thus, it is necessary 
to have a relatively long treatment duration with herbal 
medicines as well as the duration of  the follow-up period; 
Funnel plot of  inclusion trials indicated asymmetry, the 
major interpretation is the presence of  publication bias 
and variable methodological quality. In the studies that 
we reviewed, 18 out of  22 were conducted in China and 
published in Chinese. Chinese studies more frequently 
showed favorable therapeutic results compared to articles 
in English, particularly those with a high rate of  positive 
outcome (99%)[32]. The large number of  poor quality 
studies is another source of  bias. Furthermore, the small 
size of  studies and the variability of  the control treatment 
may cause asymmetry of  the funnel plot. We noticed that 
most of  the studies with Chinese herbs were of  poor 
methodological quality and would not provide strong 
evidence to confirm the efficacy of  CHM. However, 
the lack of  good evidence supporting the effectiveness 
of  CHM does not mean that these preparations are not 
effective in the treatment of  IBS, instead we need to 
improve the methodological quality of  trials in order to 
verify the efficacy of  CHM as a therapeutic approach. 
We agree with the opinion of  Liu[33] that the potential 
beneficial effects of  CHM need to be confirmed in 
rigorous trials with well-designed, randomized, double 
blinded, placebo controlled studies. A good example is the 
study performed by Bensoussan and colleague[11].
There is growing interest in placebo response in 
patients with IBS. A systematic review of  RCTs showed 
that global improvement in IBS symptoms with placebo 
was 40.2% (range 16%-71.4%)[34].Other investigators have 
reported placebo response rate of  57% in IBS[35]. Placebo 
response rate correlated with factors such as frequency 
of  intervention, methodological quality of  study, duration 
of  the study, the patient-practitioner interaction and the 
diagnosis treated[34,36-38]. Since the number of  studies using 
placebo were small, we did not explore the response effect 
of  placebo in the present study.
Table 2  The type and frequency of adverse events reported in 
the 22 studies included in the analysis (n  = 1279)
Adverse events Number of 
adverse events
Percentage 95% CI
Distention 9 0.70   0.32-1.34
Diarrhea 8 0.63   0.27-1.23
Abdominal pain 6 0.47   0.17-1.02
Constipation 5 0.39   0.13-0.91
Dizziness and sleepiness 4 0.31   0.09-0.80
Headaches 4 0.31   0.09-0.80
Nausea 3 0.23   0.05-0.69
Gastrointestinal discomfort 1 0.08 0.002-0.44
Upper gastrointestinal 
discomfort
1 0.08 0.002-0.44
Loss of hair 1 0.08 0.002-0.44
Pruritus 1 0.08 0.002-0.44
Paraesthesia 1 0.08 0.002-0.44
Disturbance 1 0.08 0.002-0.44
Hoarseness 1 0.08 0.002-0.44
Shortness of breath and 
chest pain
1 0.08 0.002-0.44
Total            47 3.67   2.73-4.87
01 Gegan Qinlian pellet
     Liu 2003[23]     38/41    26/36
Subtotal (95% CI)     41    36
Total events: 38 (Treatment), 26 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P  = 0.03)
02 Wuma Simo decoction
     Wang 2003[22]     46/52    43/52 
Subtotal (95% CI)     52    52
Total events: 46 (Treatment), 43 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P  = 0.40)
100.00  1.28 [1.03, 1.60]
100.00  1.28 [1.03, 1.60]
100.00  1.07 [0.91, 1.25]
100.00  1.07 [0.91, 1.25]
Study    Treatment  Control       RR (fi xed)  Weight        RR (fi xed)
or sub-category       n /N    n /N         95% CI     %          95% CI
      0.1    0.2         0.5     1       2         5       10
             Favours CM            Favours HM
Figure 5  Comparison of herbal medicine and conventional medicine (Outcome: constipation). HM: Herbal medicine; CM: Conventional medicine; RR: Relative risk; CI: 
Confi dence interval; Fixed: Fixed effects model.
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Figure 6  Funnel plot. Fixed: Fixed effects model; RR: Relative risk.
www.wjgnet.com
460        ISSN 1007-9327       CN 14-1219/R     World J Gastroenterol         January 21, 2008    Volume 14     Number 3
In the 22 trials that we reviewed, there were only 15 
adverse events associated with HM. These were abdominal 
distention, constipation, abdominal pain, diarrhea, dizziness 
and hypersomnia, headache and nausea. However, no serious 
side effects or abnormalities of  laboratory parameters such 
as liver function, renal function or haematological tests were 
reported with the treatment. Studies conducted in the West 
reported more adverse events than those from China. It is 
possible that because of  the lack of  rigorous monitoring, 
several adverse effects including serious events may not have 
been reported. Similarly, because of  publication bias, adverse 
events related to herbal medicine may not be reported 
properly.
In summary, the use of  HM for treating IBS is increasing 
worldwide. Most of  the studies included in our review 
showed a benefi cial effect on IBS symptoms.  However, the 
methodological quality of  the studies was variable, with 82% 
being of  poor quality which may have overestimated the 
effectiveness of  treatment. Although adverse events arising 
from the use of  herbs were mild and infrequent, HM should 
be used with caution because of  the reasons discussed 
above. It is therefore necessary to conduct Level I studies in 
order to provide evidence for Grade A recommendations[39] 
and clarify whether Chinese herbal medicines are reliable 
and safe therapy in IBS.
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